Eli Lilly and Company

Bayer Pharmaceuticals Corporation

Pfizer Corporation

Bayer Healthcare LLC

Chemwerth, Inc.

Bayer Pharma Aktiengesellschaft

Sidney Xi Liang

Yao-Chang Xu

Daniel Timothy Kohlman

Steven R Magnuson

William H Bullock

Eric Mull

Soongyu Choi

Jill E Wood

Roger B Clark

David Gunn

Xin Ma

Martin F Hentemann

Bai-Ping Ying

Frantz Victor

Yamin Wang

Matthew Frank Brown

Mark Edward Flanagan

Adam Matthew Gilbert

Matthew Joseph Fisher

Timothy Paul Burkholder

David T Wong

Joseph P Burkhart

Matthew Merrill Hayward

Stephen W Kaldor

Atli Thorarensen

Rayomand Jal Unwalla

Yanping Xu

John Isidro Trujillo

James E Fritz

Larry W Hertel

Ye Che

Shawn Christopher Miller

Karin Briner

Agustin Casimiro-Garcia

Stephen Boyer

Philip L Wickens

Louis-David Cantin

Ning Qi

Joachim Rudolph

Dyuti Majumdar

Libing Chen

Michael Philip Cohen

Rico C Lavoie

Deyi Zhang

Qingjie Liu

Tindy Li

Christiana Akuche

Chih-Yuan Chuang

DeAnna Piatt Zacherl

Donglei Liu

Jeffrey Thomas Mullaney

Vincent Mancuso

Jean-Baptiste Telliez

William Harlan Gritton

Ann-Marie Bullion

Xiping Su

Alan Olague

Peter J Werth

David Cantin

Ellalahewage Kumarasinghe

Herbert Ogutu

Upinder Singh

John I Trujillo

Deanna Piatt Zacherl

The disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula (I) The variables, R, R!-R3 and the A-ring are described herein. A can be a cyclohexyl ring. The compounds are inhibitors of JAK1 Kinase and are useful in methods of treating an allergic, inflammatory, or autoimmune disorders, in a patient, comprising administering a therapeutically effective amount of compound of Formula I or salt thereof, to the patient. The disclosure also provides pharmaceutical formulations containing a compound of Formula I.

Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof

The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where;  The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

[object Object]

This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases and to pharmaceutical compositions containing these compounds.

Indane acetic acid derivatives and their use as pharmaceutical agents

The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; Ris C-Calkyl, substituted C-Calkyl, C-Ccycloalkyl, substituted C-Ccycloalkyl, C-Ccycloalkyl-C-Calkyl, substituted C-Ccycloalkyl-C-Calkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C-Calkyl, C-Ccycloalkyl-C-Calkyl, or a group of formula II  Ris hydrogen or C-Calkyl; Ris hydrogen, halo, or C-Calkyl; Ris hydrogen or C-Calkyl; Ris hydrogen or C-Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

The present invention relates to anilinopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.

Anilinopyrazole derivatives useful for the treatment of diabetes

The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C&#x2014;R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.

1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders

The present invention provides serotonergic aminoalkylbenzofurans of Formula (I): where R, R, R, R, R, R', R, R&#x2032;, and Rare as described in the specification. 

Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists

The invention relates generally to naphthyridine derivatives of the formulawherein one of U, X, Y and Z is nitrogen and the others are C&#x2014;R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.

1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders

The present invention provides compounds of formula (I) and a method of inhibiting the reuptake of serotonin and antagonizing the serotonin receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of formula (I).

Piperidine derivatives as reuptake inhibitors

Piperidine derivatives as serotonine reuptake inhibitors

Piperidine derivatives having effects on serotonin related systems

This invention provides novel 5-HT.sub.1F agonists of formula ##STR1## where X, Y, Z,and R are defined in the specification, which are useful for the prevention and treatment of migraine and associated disorders.

Serotonin 5-HT.sub.1F agonists

Growing community of inventors

Bethany, CT, United States of America

Sidney Xi Liang